Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A tale of two antibodies: obinutuzumab versus rituximab
Ciara L. Freeman, Laurie H. Sehn
British Journal of Haematology (2018) Vol. 182, Iss. 1, pp. 29-45
Open Access | Times Cited: 154

Showing 1-25 of 154 citing articles:

ImmunoPET: Concept, Design, and Applications
Weijun Wei, Zachary T. Rosenkrans, Jianjun Liu, et al.
Chemical Reviews (2020) Vol. 120, Iss. 8, pp. 3787-3851
Open Access | Times Cited: 364
Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study
Lihua E. Budde, Sarit Assouline, Laurie H. Sehn, et al.
Journal of Clinical Oncology (2021) Vol. 40, Iss. 5, pp. 481-491
Open Access | Times Cited: 230
Lupus nephritis: new progress in diagnosis and treatment
Yu Chen, Ping Li, Xin Dang, et al.
Journal of Autoimmunity (2022) Vol. 132, pp. 102871-102871
Closed Access | Times Cited: 90
Control of acute myeloid leukemia by a trifunctional NKp46-CD16a-NK cell engager targeting CD123
Laurent Gauthier, Angéla Virone-Oddos, Jochen Beninga, et al.
Nature Biotechnology (2023) Vol. 41, Iss. 9, pp. 1296-1306
Open Access | Times Cited: 62
Genetics of glycosylation in mammalian development and disease
Pamela Stanley
Nature Reviews Genetics (2024)
Closed Access | Times Cited: 15
The emergence of drug resistance to targeted cancer therapies: Clinical evidence
Ana Bela Sarmento‐Ribeiro, Andreas Scorilas, Ana Cristina Gonçalves, et al.
Drug Resistance Updates (2019) Vol. 47, pp. 100646-100646
Closed Access | Times Cited: 112
The Role of Complement in the Mechanism of Action of Therapeutic Anti-Cancer mAbs
Josée Golay, Ronald P. Taylor
Antibodies (2020) Vol. 9, Iss. 4, pp. 58-58
Open Access | Times Cited: 77
Future landscape for the management of membranous nephropathy
Fernando Caravaca‐Fontán, Federico Yandián, Fernando C. Fervenza
Clinical Kidney Journal (2023) Vol. 16, Iss. 8, pp. 1228-1238
Open Access | Times Cited: 24
Advancements in cancer immunotherapies targeting CD20: from pioneering monoclonal antibodies to chimeric antigen receptor-modified T cells
Agnieszka Dąbkowska, Krzysztof Domka, Małgorzata Firczuk
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 8
From Biology to Therapy: The CLL Success Story
Deyan Y. Yosifov, Christine Wolf, Stephan Stilgenbauer, et al.
HemaSphere (2019) Vol. 3, Iss. 2
Open Access | Times Cited: 63
Customized protein glycosylation to improve biopharmaceutical function and targeting
Linde Van Landuyt, Chiara Lonigro, Leander Meuris, et al.
Current Opinion in Biotechnology (2018) Vol. 60, pp. 17-28
Open Access | Times Cited: 63
Targeting B Cells to Modify MS, NMOSD, and MOGAD
Jonas Graf, Jan Mareš, Michael Barnett, et al.
Neurology Neuroimmunology & Neuroinflammation (2021) Vol. 8, Iss. 1
Open Access | Times Cited: 49
TCR β chain–directed bispecific antibodies for the treatment of T cell cancers
Suman Paul, Alexander H. Pearlman, Jacqueline Douglass, et al.
Science Translational Medicine (2021) Vol. 13, Iss. 584
Open Access | Times Cited: 47
Strategies to control therapeutic antibody glycosylation during bioprocessing: Synthesis and separation
Elizabeth M. Edwards, Maria Livanos, A. P. Krueger, et al.
Biotechnology and Bioengineering (2022) Vol. 119, Iss. 6, pp. 1343-1358
Open Access | Times Cited: 35
Efficacy and safety of obinutuzumab in systemic lupus erythematosus patients with secondary non-response to rituximab
Jack Arnold, Shouvik Dass, Sarah Twigg, et al.
Lara D. Veeken (2022) Vol. 61, Iss. 12, pp. 4905-4909
Open Access | Times Cited: 31
Obinutuzumab in Frequently Relapsing and Steroid-Dependent Nephrotic Syndrome in Children
Claire Dossier, Stéphanie Bonnéric, Véronique Baudouin, et al.
Clinical Journal of the American Society of Nephrology (2023) Vol. 18, Iss. 12, pp. 1555-1562
Closed Access | Times Cited: 21
Hypogammaglobulinemia, late-onset neutropenia, and infections following rituximab
Tejas S. Athni, Sara Barmettler
Annals of Allergy Asthma & Immunology (2023) Vol. 130, Iss. 6, pp. 699-712
Open Access | Times Cited: 19
NETosis: an emerging therapeutic target in renal diseases
Márk Juha, Adél Molnár, Zoltán Jakus, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 19
T-cell help in the tumor microenvironment enhances rituximab-mediated NK-cell ADCC
Jyoti Arora, Sabarish Ayyappan, Chaobo Yin, et al.
Blood (2024) Vol. 143, Iss. 18, pp. 1816-1824
Closed Access | Times Cited: 7
An Updated Review of Membranous Nephropathy
Orhan Efe, Paolo Nikolai So, Urmila Anandh, et al.
Indian Journal of Nephrology (2024) Vol. 34, pp. 105-118
Open Access | Times Cited: 6
Childhood, adolescent and young adult non‐Hodgkin lymphoma: current perspectives
Mitchell S. Cairo, Auke Beishuizen
British Journal of Haematology (2019) Vol. 185, Iss. 6, pp. 1021-1042
Open Access | Times Cited: 50
Obinutuzumab in the treatment of B-cell malignancies: a comprehensive review
Andrew Davies, Arnon P. Kater, Jeff P. Sharman, et al.
Future Oncology (2022) Vol. 18, Iss. 26, pp. 2943-2966
Open Access | Times Cited: 22
Obinutuzumab as Initial or Second-line Therapy in Patients With Primary Membranous Nephropathy
Xiaole Su, Binxin Wu, X. Tie, et al.
Kidney International Reports (2024) Vol. 9, Iss. 8, pp. 2386-2398
Open Access | Times Cited: 5
Obinutuzumab in Refractory Membranous Nephropathy: A Case Series
Yuxin Lin, Quan Han, Liangliang Chen, et al.
Kidney Medicine (2024) Vol. 6, Iss. 8, pp. 100853-100853
Open Access | Times Cited: 5
The role of Obinutuzumab in rituximab-refractory membranous nephropathy and minimal change disease
Zewei Chen, Dechao Xu, Shuangcheng Alivia Wu, et al.
Clinical Kidney Journal (2025) Vol. 18, Iss. 3
Open Access
Page 1 - Next Page

Scroll to top